Followers | 898 |
Posts | 149062 |
Boards Moderated | 0 |
Alias Born | 08/13/2010 |
![](https://investorshub.advfn.com/uicon/213855.png?cb=1701432176)
Tuesday, January 31, 2023 7:47:19 PM
Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.
Recent JNJ News
- CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study • PR Newswire (US) • 07/02/2024 11:30:00 AM
- Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients • PR Newswire (US) • 06/28/2024 03:30:00 PM
- Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue • Business Wire • 06/27/2024 10:46:00 PM
- Johnson & Johnson Completes Acquisition of Proteologix, Inc. • Business Wire • 06/21/2024 11:30:00 AM
- Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease • PR Newswire (US) • 06/20/2024 08:30:00 PM
- More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme • Business Wire • 06/20/2024 05:07:00 PM
- TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction • PR Newswire (US) • 06/20/2024 12:00:00 PM
- Trump Media Resells Stocks and Warrants; KB Home Exceeds Q2 Expectations, and More News • IH Market News • 06/20/2024 10:55:11 AM
- Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products • Business Wire • 06/17/2024 09:55:00 PM
- Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer • PR Newswire (US) • 06/17/2024 12:00:00 PM
- Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study • PR Newswire (US) • 06/15/2024 07:30:00 AM
- TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma • PR Newswire (US) • 06/14/2024 12:00:00 PM
- Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy • Business Wire • 06/12/2024 06:26:00 PM
- Paramount Ends Skydance Talks, Oracle Shares Surge 8.7% on New Partnerships, and More News • IH Market News • 06/12/2024 11:19:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 09:07:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 09:07:29 PM
- Apollo Buys 49% of Intel’s Irish Plant for $11bn, BlackRock and Citadel to Create Texas Exchange, and More News • IH Market News • 06/05/2024 11:41:36 AM
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results • Business Wire • 06/04/2024 08:30:00 PM
- Johnson & Johnson Completes Acquisition of Shockwave Medical • Business Wire • 05/31/2024 12:45:00 PM
- Sarepta Therapeutics Set to Join S&P MidCap 400 • PR Newswire (US) • 05/29/2024 09:48:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/28/2024 08:10:27 PM
- Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis • GlobeNewswire Inc. • 05/28/2024 11:35:00 AM
- Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis • Business Wire • 05/28/2024 11:30:00 AM
- Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation • Business Wire • 05/22/2024 04:05:00 PM
- Form CERT - Certification by an exchange approving securities for listing • Edgar (US Regulatory) • 05/21/2024 02:43:01 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM